Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.56 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20943064 | 0.92 | FGFR1 (0.57) | EGFRBTKFGFR2FGFR4FGFR1 | |
| SCHEMBL20942989 | 0.86 | FGFR4 (0.58) | FGFR2FGFR4FGFR1FGFR3MAPK3 | |
| SCHEMBL20943007 | 0.86 | FGFR4 (0.55) | EGFRFGFR2FGFR4FGFR1SRC | |
| SCHEMBL20942991 | 0.85 | FGFR1 (0.50) | EGFRBTKFGFR2FGFR4FGFR1 | |
| SCHEMBL20943013 | 0.85 | FGFR4 (0.50) | EGFRFGFR2FGFR4FGFR1FGFR3 | |
| SCHEMBL20943045 | 0.85 | EGFR (0.56) | EGFRBTKFGFR4FGFR1SRC | |
| SCHEMBL20943054 | 0.84 | FGFR1 (0.59) | EGFRFGFR2FGFR4FGFR1FGFR3 | |
| SCHEMBL21019625 | 0.84 | FGFR1 (0.53) | EGFRFGFR2FGFR4FGFR1FGFR3 | |
| SCHEMBL20943040 | 0.83 | FGFR1 (0.53) | EGFRFGFR2FGFR4FGFR1SRC | |
| SCHEMBL20943031 | 0.83 | FGFR1 (0.61) | EGFRFGFR2FGFR4FGFR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696675-B2 | Imidazopyridopyrimidine derivative compound and use thereof | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2020-06-30 | — | — | US | claimed |
| US-20190152973-A1 | NOVEL HETEROCYCLIC DERIVATIVE COMPOUND AND USE THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2019-05-23 | — | — | US | claimed |
| EP-3476846-A1 | NOVEL HETEROCYCLIC DERIVATIVE COMPOUND AND USE THEREOF | Hanmi Pharmaceutical Co., Ltd. (KR) | 2019-05-01 | — | — | EP | claimed |
| US-10696675-B2 | Imidazopyridopyrimidine derivative compound and use thereof | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| US-10696675-B2 | Imidazopyridopyrimidine derivative compound and use thereof | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| US-20190152973-A1 | NOVEL HETEROCYCLIC DERIVATIVE COMPOUND AND USE THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2019-05-23 | — | — | US | disclosed |
| US-20190152973-A1 | NOVEL HETEROCYCLIC DERIVATIVE COMPOUND AND USE THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2019-05-23 | — | — | US | disclosed |
| EP-3476846-A1 | NOVEL HETEROCYCLIC DERIVATIVE COMPOUND AND USE THEREOF | Hanmi Pharmaceutical Co., Ltd. (KR) | 2019-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696675-B2 | Imidazopyridopyrimidine derivative compound and use thereof | FGFR1, FGFR4, FGFR3 | EGFR 16/4885BTK 88/4885FGFR2 4/4885 |
| US-20190152973-A1 | NOVEL HETEROCYCLIC DERIVATIVE COMPOUND AND USE THEREOF | FGFR1, FGFR3, FGFR2 | EGFR 26/4885BTK 326/4885FGFR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.